UPDATE 1-FTSE 100 falls as inflation concerns weigh

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)
* Boris Johnson to decide on easing in lockdown measures
* AstraZeneca (NASDAQ:AZN) falls after withdrawing cancer drug use
* IAG gains after a liquidity raise
* FTSE 100 down 0.7%, FTSE 250 off 0.8%

(Adds comment, updates prices)
By Shivani Kumaresan
Feb 22 (Reuters) - London's FTSE 100 fell on Monday as
higher commodity prices sparked fears of a spike in inflation,
while investors awaited Prime Minister Boris Johnson's plan for
a phased easing of business restrictions.
The blue-chip FTSE 100 .FTSE fell 0.7%, led by declines in
consumer staples and industrials stocks.
Oil heavyweights BP BP.L and Royal Dutch Shell RDSa.L
dipped 0.1% and 0.4%, respectively, despite a rise in crude
prices. O/R
Johnson will plot a path out of COVID-19 lockdown on Monday
in an effort to gradually reopen the battered $3 trillion
economy, aided by one of the fastest vaccine rollouts in the
world. "Any inflation that's coming will be affecting the supply
chain with a grid-locked type scenario where you can't get the
goods you want," said Keith Temperton, a sales trader at Forte
Securities.
The FTSE 100 has recovered nearly 35% from its March 2020
lows and is nearly 13% away from its highest level last year,
thanks to record stimulus measures and massive vaccine rollouts.
The mid-cap index .FTMC fell 0.8%, with G4S Plc GFS.L
being the biggest drag on the index after Canada's GardaWorld
said it would not raise its offer, appearing to leave the way
clear for the higher bid lodged by rival Allied Universal to
succeed. British Airways-owner IAG ICAG.L rose 1.4% after it said
it raised total liquidity by 2.45 billion pounds ($3.4 billion)
by reaching final agreement for a 2-billion-pound loan and
through a deal to defer 450 million pounds of pension deficit
contributions. Pub operator Mitchells & Butlers MAB.L rose 9.7% despite
reporting a plunge in sales as all its sites were forced shut
under the latest lockdown. Drugmaker AstraZeneca AZN.L fell 0.3% after voluntarily
withdrawing the use of its cancer drug Imfinzi to treat advanced
bladder cancer in the United States after it failed to meet
post-approval requirements.